Roberto. you, Thank
Turning now disease. infectious to
as We come established in XXXX. QX. increase the X deliver HIV HIV strong countries international rose to up continue begin XX% with -- in revenue shipped increasing quarter first This increases continued XX% driver and Self-Tests of compared the to new business international to to million scale to business year-ago a was Major quarter, in online. to countries quarter HIV global XX% first revenue. testing markets performance the compared Our
Our the business X% was quarter. domestic for first down
our domestic global COVID-XX pandemic is having on its impact and greatest HCV business HIV business.
significantly quarter, domestic quarter, affected. were which HIV During our the started either for first testing professional results not QX reduced on in products. programs the or lowered were most later hold, Because demand it our put
international year, shipping HIV good were remains the future have the If to little overseas, experienced which issues it contrast, in on effectively. to able to the pandemic of there's COVID-XX In begins believe resulting our testing COVID-XX product we strong, sales relatively only periods. manage we a minor from by will we HIV and middle chance subside impact a Self-Test related
However, impact to resolved, domestic we on the COVID-XX COVID-XX on from continue stay-at-home expect depend exact the in the and downward will when How pandemic revenue long HIV social restrictions distancing pressure business. the last lifted. will is and this revenues and are the
under has Uganda, about Tanzania, Apart new India, of countries: STAR, Self-Testing COVID-XX, indicated III optimistic HIV International from Mozambique, it will the we X Africa, Phase Population extend and initiative. remain or Indonesia, that initiative Self-Testing. Services Cameroon to Nigeria,
Phase the the begin fourth of is expected to second third tests in additional to in provide on under receive to scale. to with HIV drive it expect Phase occurring start be We will phase will this programs the to shipments for Size the and I. Self-Testing quarter, Not assistance program additional quarters. III only XXX,XXX orders volume, a similar purchased countries under also national
U.S. Plan social President's pandemic during its continuing is this AIDS consider increasing or which a HIV/AIDS global epidemic, to COVID-XX a address Emergency distancing. has communicated self-testing the HIV Relief initiative for to to of as maintaining governmental In the guidance regard, countries way testing while the funded PEPFAR,
Self-Testing HIV recognized domestically. is face of also value the The being COVID-XX of in
FDA-approved increasing test many Although order to in-home without in a of testing being clients to sales impacted, enable are to professional departments our their HIV having are health our HIV continue HIV purchases of to tests negatively come public clinic.
In order COVID-XX Prevention testing all with Centers complying to Disease letter Control just restrictions. issued continue their sites, to encouraging in fact, to in-home HIV for the and last them week self-testing funded use a safety while for
expect offset the franchise. impacted, FDA-approved HIV our the our be downward have will will pressure HIV on we revenues only we in-home it Since Self-Test, although positively not fully likely professional
course, depend the ultimate mitigate. on begins when impact to Of will COVID-XX the situation
business to of response in have briefly Turning part both on this when Many QX hold resolved, our Depending to from COVID-XX testing to prior situation the personnel on this money in revenue. business being programs the U.S. to eventually normal HCV. the and been as shifted levels Revenues COVID-related we anticipate activities. year. put more is declined compared return to would of
COVID-XX it sales in business was Our lower declined in due although international not to materially by Asia. QX, affected
previously everything have from and by funding planned, development oral If of fluid market uses the use pay cost hope of challenges This Biomedical a XXXX. the As a despite FDA. pan-SARS antigen develop BARDA, receipt help samples. an early test of COVID-XX, for Development mentioned, In on coronavirus be to or could to with and contract will related Advanced a that the substantial. we see we number authorization, in-home EUA, upside the goes fall opportunities rapid self-test the emergency Research announced to as which we Authority, April, this
an We health and or a that health detection a pressure will sample an collect The fluid and while has BARDA current reduce easier painful protecting like reference home an oropharyngeal oral using to on antigen as that care it oral that individuals said providers. the could this systems infections test value overburdened game believe, of by a fluid than at sample. is allow laboratories changer publicly, by care will is self-test nasopharyngeal be of less
who of communities our safeguard infected with identifying our economy. Testing their them and restart COVID-XX home, millions isolating will and in peoples those are help
of show equipment. it receipt collection other antibodies We an device. activities. COVID-XX high-volume We OraSure to past and EUA to Antibody run home test fluid test is this contemplate Completion targeted more this approval can determine mail for collect laboratory testing. using will easily helping acquired laboratory patients be work sample oral for if normal immunity early return tests be will to to allow and test people a used specimen to have infection, our safely and Samples would their summer. be of to developing on oral that self-collected microplate coronavirus are also for and at
Finally, we with are and both pursuing organizations, international. domestic multiple collaborations
fund scenarios production assumptions products. and these our Some an to of demand various as help to of for intended we capacity demand potential meet expansion are high model
of collaborations are testing than we are ones the third-party We commercialization currently and exploring for internally. development different coronavirus products developing
We will provide on they updates appropriate these develop. collaborations as
the up to Molecular Revenues molecular compared Turning Solutions our from segment. to QX were XXXX. business XX%
purchases but collection greater saliva organic difficulties the in and a a customers number business saliva some genomics COVID-XX given with of samples blood environment. increased shifting obtaining blood and delivered a Our who combination on to are growth used commercial strong historically reliance a now from the of performance
XX a genomics XX% and increase microbiome customers number in new are customers in our some in as added QX products, cases commercial We that both using services the and of reported well.
received a general Dx the products. strengthens assays. test and for regulatory Oragene for clearance molecular Oragene our and providers the competitive reduces for our as Dx During burden to QX, collector position market we family use in This approved clearance of XXX(k) their an adopt
disease growth return to the activities confident to our and results, risk submarket of market. as COVID-XX COVID-XX kits Despite remain of customers many first previously, mentioned the We sales testing. urine impacted management business our microbiome This this by sales with pandemic. the academic market were affected genomics as quarter to strong associated negatively that double-digit our not microbiome collection and after and genomics, research delayed both these customers annual the will
in our of a to for may Infectious increased revenue related Molecular any than could impact and segment. significant the Disease with As be business segments, more seeing now COVID-XX. opportunities These we're negative number offset
nasopharyngeal medical alternatives to accepted the sample for collection COVID-XX testing of testing. current and overall With capacity, community issues seeking the collecting oropharyngeal standard and samples the is with
the addition COVID-XX. that of in being have and comfortable is quicker workers, sample to superior to publications saliva, collect health for both more for technically patients and indicated Several type care detection
specifically RNA Dx, for this and purpose. ORAcollect Oral Our lines, Oragene OMNIgene product well suited are
proprietary RNA. stabilizing Our and chemistries stabilization in effective proven viral DNA are be to
in both customers for Dx clearance. easy this samples granted nontoxic been it Our COVID-XX products for of by home of or device making supervision an line the and settings at is in home is has use, safe, It and type ideal clinic. of of millions XXX(k) device Oragene only either self-collection professional under to used the testing, and
hospitals. with working assays leading tests the use span To all collection date, tests, of that least COVID-XX feel of devices approximately extraction QX expected world several with shipped customers kits revenue, million have expected over common diagnostic are with shipped to including with products have and XXX and with labs at We who in collection offered share provide over goal: be all of $X.X These techniques solutions. some to and XX confident sample our and shortly. laboratories date, customers to types in-house test scope our COVID of to we and companies validate we platforms. for -- X XX we've and To to teaching COVID will over of broaden easy-to-use result genetic providers, the testing the validations manufacturers COVID-XX commercial customers for more engaged now from significance in purchase orders compatible
kit on by COVID-XX authorizes Biocerna, for collection the testing COVID-XX the devices week related As This last ORAcollect nasal the use samples the was one Monday, issued LLC. first anterior FDA our authorization, to Biocerna assay. of emergency of RNA use or our EUA, EUA with we for incorporating of announced
for and using settings. EUAs first samples our in We expect to of professional saliva testing either be or the devices nasal several at-home this COVID-XX incorporating
studies generating regulatory is the These and these at-home we safety and In using testing. for customers, usability to ongoing our addition confirm our we sample collection encouraging, to data to are clearances. have studies data to from of own studies look collection. support we with expand include the our our of to devices the several COVID-XX results Preliminary forward
that To suppliers. products, multiple at we're our increasing increased been our seeing for meet demand we the capacity have
We our expect shifts help leverage production capabilities. be product to to -- multiple able our to increase
existing seen we've area, service commercial lab demand with for consistent lab a projects. services the in from microbiome customers dedicated our Finally,
anticipate as services the companies COVID-XX. refocus short-term we a pharmaceutical However, microbiome overall weakening due in market major efforts to
academic to limited delays noted I there been COVID-XX to some previously, due have the restrictions access samples. microbiome in market because of As
microbiome Paul, Diversigen operation service state-of-the-art our as On integrate well the absorb foot designed This to completion XX. in to operations Xth, CoreBiome and our as mid-May is XXX% and bioinformatics of on target our customers laboratory the laboratory for part new, of continuing facility St. a to are has integration both Relocation near expected of will We in legacy operations square XX,XXX businesses. operational facility quarter May CoreBiome software the The the Minnesota. been will relocate XXXX. a date end teams. laboratory lab to Diversigen the May of be for begin with third CoreBiome
with Diversigen physical consolidating we'll the be for integration, Along service name. the organizations branding microbiome the under
in operating We weeks, final within Diversigen be stretches services will the are few for microbiome with work. this the a logo. And new rebranding name under all next the
rapid cover to substantial topic business be in dedication has is retirement. and be growth including in final with Tony leadership and of and summer. recent company our of who disease years the I made will Zezzo, been changes we charge have the announced. organizational well the unit, will HCV business our the contributions, Tony this global commercialization infectious leader retiring our certainly want in and wish has steady the XX franchise. his we test His missed for almost A unit him significant is HIV
and other Vice leader successor joining after BD Tony's we our at segment with as Orasure needed has extensive that and I'm Dickinson, past Medication recently Manager years business. BD's both of large companies X General Delivery exactly of Becton responsibility, general business. this be skills for a confident will role. important in Nibauer, this and for strong the President Solutions Lisa management, will will Lisa the be for marketing be and sales has most she serving
and Committee the has long Affairs, Dr. changes. and Secretary U.S. career We've be history public leadership Board. him -- Committee. a month of record has now Veterans the and federal His will the enable David government. level to at highest of fields announced and executive of served the Nominating Corporate Board in Shulkin, distinguished strong on health the within joined was formerly medical, Department our serving health David Audit also the significant is last and a public and contributor several recently track Governance Board to
also the of Committee, upcoming Board X Dr. Nominating our currently as will joined she departure leaving the in Sarin, XXXX that annual so devote the and announced Chair time the Committee be Governance and serves We meeting the members. can Alexion Audit to Corporate Chief more of as of Aradhana And our duties Officer and who Board Board a member prior Pharmaceuticals. to Financial of
addition, serves member Audit member and Patrick, Nominating has and of years a effective the almost the the who as and will May for Corporate a Board Chuck XXth. Governance with be been Board the of from In retiring XX Committee Committee
advice them strong their wish success contributors counsel Board in been the endeavors. and much and Chuck have and missed. will to both Aradhana Both future be We their
in In of pandemic. XXXX a performance to is spite good QX the closing, with solid a start off
is grow Our HIV continue business Self-Testing expected to strongly. to
of to believe COVID-XX the new saliva molecular rapid well in use test of a the expertise could opportunity pandemic. generate help a We laboratory-based antigen expanded the result collection any are We revenues and COVID-XX. promising excess are our fluid proud with revenue loss fluid products, of is along to as test, for antibody and fight in-home our oral coronavirus a oral leverage
future environment, is uncertain the bright. our current Despite
are financially. strong We
forward to any significant We external continued back have successfully time, and strategy, growth continue pursuit become opportunities the developments the capabilities available. and they At look before execute us. our Board acquisitions. technical capture enable innovation us we new the same management evaluation reporting to the as of to on We to against
we your that, Operator, with And will questions. now proceed. take please
